Investigational Site Number :4100005

Seongnam-si, Gyeonggi-do 463-707

0 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, Chronic Obstructive Pulmonary Disease

Studies at this site

• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early